Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients

University of Cologne30 enrolled

Overview

The purpose of this study is to determine within the scope of the trial what the maximum tolerated dose (MTD) of lenalidomide in combination with AVD should be.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Hodgkin Lymphoma

Interventions

DoxorubicineDRUG

50mg/m2 day 1 + 15

DTICDRUG

375mg/m2 day 1 + 15

LenalidomideDRUG

day 1 - 21

Vinblastine

Eligibility

Sex: ALLMin age: 60 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Hodgkin Lymphoma, intermediate or advanced stage * Age \>60 and \<75 years * ECOG 2 or better * No major organ dysfunction * Ability to take aspirin or LMW Heparin Exclusion Criteria: * HL as composite lymphoma * Prior use of lenalidomide * Prior use of chemo- or radiotherapy

Locations (1)

1st Dept. of Medicine, Cologne University Hospital

Cologne, North Rhine-Westphalia, Germany

Outcomes

Primary Outcomes

Dose limiting toxicities (DLT)

Secondary Outcomes

Overall response rate (ORR)

Progression free survival (PFS)

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.